Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin + durvalumab with endoscopic radiofrequency ablation for unresectable biliary tract cancer with biliary obstruction
jRCTs051230119Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, gemcitabine and cisplatin in biliary cancer, sponsored by AstraZeneca. Primary endpoint: Percentage of serious adverse events. Started Jan 2024; status: active, not recruiting.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs051230119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230119.